A comprehensive understanding of the interplay between senescence, Bcl-2 dependency, and molecular heterogeneity in MM is essential for optimizing senolytic therapies and tailoring effective treatment strategies. This evidence concerns the gene BCL2 and Miyoshi myopathy.